What the LoDoCo2 Trial Says About Low-Dose Colchicine for Residual Cardiovascular Risk

A daily 0.5 mg dose of colchicine, an old and inexpensive gout drug, lowered the rate of major cardiovascular events by roughly a third in people with stable coronary disease who were already on good background therapy. That is the headline from LoDoCo2, a trial of 5,522 patients published in the New England Journal of Medicine in 2020. The result is one of the clearest randomized signals that inflammation, not just cholesterol, is worth treating in established heart disease. It also came with a mortality footnote that keeps the story from being tidy.

Key points#

• LoDoCo2 randomized 5,522 patients with chronic coronary disease to 0.5 mg colchicine daily or placebo, with a median follow-up near two and a half years.
• The primary composite (cardiovascular death, heart attack, ischemic stroke, or ischemia-driven revascularization) fell from 9.6 percent to 6.8 percent, a hazard ratio of 0.69.
• The benefit held for the hardest outcomes, including spontaneous heart attack, so it is unlikely to be a statistical artifact.
• Non-cardiovascular deaths were numerically higher in the colchicine group, an unresolved signal rather than proven harm.
• A pre-trial tolerance period means real-world side effects may look messier than the trial reported.

Why "residual risk" points at inflammation#

Modern secondary prevention is good. Statins, blood-pressure control, antiplatelet drugs, and smoking cessation each move the needle. Yet a stubborn fraction of well-treated patients still have heart attacks and strokes. Cardiologists call that leftover danger residual risk, and a growing body of evidence says part of it is driven by inflammation in the artery wall rather than by cholesterol alone.

The biology fits. An atherosclerotic plaque is not an inert lump of fat; it is an inflamed, unstable structure, and the ones that rupture tend to be the inflamed ones. Blood markers of inflammation, such as high-sensitivity C-reactive protein, predict future events even after accounting for LDL. If that inflammatory component is real and modifiable, then calming it should lower the event rate. Colchicine is a plausible tool because it blunts the inflammasome pathway and the neutrophil activity that feed plaque instability, and it has been used safely for gout and pericarditis for generations.

How the trial was built#

LoDoCo2 enrolled patients in Australia and the Netherlands who had documented coronary disease and were clinically stable. One design choice matters a great deal for how you read the result. Before randomization, everyone went through an open-label period on colchicine, so patients who could not tolerate the drug were screened out first. Only those who passed that tolerance check were then randomized to 0.5 mg of colchicine once daily or matching placebo.

This run-in makes the trial cleaner but also less representative. By the time the coin was flipped, the study population was already enriched for people who get along with the drug. That improves the chance of detecting a true effect, and it means the tolerability seen in the trial is more flattering than what a clinic full of unselected patients would experience.

The result, and what a composite can hide#

Over a median follow-up of about two and a half years, the primary composite endpoint occurred in 6.8 percent of the colchicine group and 9.6 percent of the placebo group. The hazard ratio was 0.69, with a 95 percent confidence interval of 0.57 to 0.83. In plain terms, the relative risk of that bundle of events dropped by roughly 31 percent, and because the confidence interval sits well below 1.0, chance is an unlikely explanation.

A composite endpoint is a double-edged tool. Combining four outcomes raises the event count and makes a trial more efficient, but it can also let a soft component do the heavy lifting. Here the softest of the four is ischemia-driven revascularization, because the decision to reopen an artery leans partly on physician judgment and symptoms rather than on a clean, hard event. That is the question to put to the trial: did the benefit ride mainly on revascularization, or on the outcomes that are harder to dispute?

The reassuring answer is that the harder components, including spontaneous heart attack, moved in the same favorable direction. That coherence argues for a real biological effect rather than a quirk of one soft measure. Even so, the honest framing is a relative reduction of about a third layered on top of good therapy, not a rewrite of a patient's prognosis. The absolute gap between the groups was a few percentage points across the follow-up window, and that absolute number is the one that matters most when you are deciding whether to add a pill.

LoDoCo2 did not appear out of nowhere. It built on a smaller earlier LoDoCo trial and on CANTOS, which had shown that a targeted anti-inflammatory antibody reduced events but at high cost and with its own infection risk. Colchicine offered a cheap oral alternative, and LoDoCo2 gave the idea a properly powered test.

The mortality question#

The caveat that deserves the most attention is not about whether colchicine works. Cardiovascular deaths were similar between the two groups, but the colchicine arm recorded numerically more non-cardiovascular deaths, and total mortality drifted upward rather than down. The trial was not powered to settle whether that difference is a genuine hazard or a play of chance, and later pooled analyses have not confirmed a clear mortality harm. Still, an unexplained rise in deaths from other causes is exactly the kind of signal that should cool enthusiasm and argue for longer follow-up.

There is also the drug itself to respect. Colchicine has a narrow margin between benefit and toxicity. It interacts with common medications, including some statins and agents that slow its metabolism, and it can cause gastrointestinal upset and, rarely, muscle and bone-marrow toxicity. Because the trial pre-selected people who tolerated it, everyday use is likely to surface more side effects than the published numbers imply.

Where the evidence sits now#

LoDoCo2 moved low-dose colchicine from an interesting hypothesis to a trial-backed option that now appears in discussions of secondary prevention, and it helped push inflammation onto the list of modifiable cardiovascular targets. Professional societies have folded it into their conversations about established coronary disease, and regulators approved a low-dose colchicine formulation for cardiovascular risk reduction. A regulatory approval describes what a label legally permits and for which group of patients; it is not a verdict that a specific person should take the drug, and it is not a clean bill of safety.

None of this makes colchicine a routine add-on for everyone with a coronary stent. It is a specific tool, tested in a specific stable population, with a benefit that is real but modest and a mortality question that stays open. Decisions about it belong in a conversation between you and your own clinician, weighed against everything else on your medication list.